| Improved Quality of Life for Head and Neck Cancer Patients with Nivolumab Intellisphere, LLC (press release) (registration) (blog) Patients with cancer of the oral cavity, pharynx, or larynx were randomly assigned to 3 mg/kg nivolumab every 2 weeks (n = 240) or investigator's choice of cetuximab (12.4%), methotrexate (44.6%), or docetaxel (43%; N = 121). Cetuximab was administered ... |
from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2uoap0c
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,